SweetNight Proudly Introduces the All-New CoolNest(TM) Memory Foam Mattress
Wilmington, Delaware--(Newsfile Corp. - May 20, 2025) - SweetNight, a trailblazer in sleep innovation, introduced the CoolNest™ Memory Foam Mattress, its most advanced cooling sleep solution to date. Engineered specifically for individuals who experience overheating or night sweats, the mattress is designed to improve sleep quality by maintaining a consistently cooler and more comfortable sleeping environment, which has quickly become the new favorite of most hot sleepers and night sweaters.
This mattress is tailor-made for hot sleepers, night sweaters, back pain sufferers, and anyone who believes a better day starts with deeper rest. With temperature regulation so effective it's been described as " cool enough for a polar bear," the mattress delivers measurable comfort benefits for those seeking better sleep and better mornings.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=BR6FMRHzm5U
Designed with SweetNight's proprietary CoolNest™ Cooling System, the mattress delivers up to 8° cooler sleep temperatures, offering a much-needed escape from night sweats and sleep disruptions.
The magic begins with the CoolNest™ Cover, engineered with 3D weaving technology and over 10,000 micro-ventilation pores to boost breathability by 35%. The PCMflux™ High Resilience Foam in the middle features a hollow core structure that is three times more breathable than standard foams and is infused with an advanced phase change material (PCM) that stabilizes body temperature during the night.Enjoy a cool and cozy night's sleep
But the CoolNest™ Memory Foam Mattress isn't just cool, it's also designed with an ergonomic 5-zone support for excellent support. Certified by the American Chiropractic Association (ACA), the mattress is meticulously designed to maintain spinal alignment, relieve pressure points, and improve overall sleep posture. By addressing common causes of poor sleep such as misalignment and tension, CoolNest™ enables users to recover more effectively overnight, improve mobility, and start each day with greater energy, focus, and resilience. Whether you're a side sleeper, back sleeper, or someone who changes positions frequently, the mattress adapts intelligently to your body-transforming rest into a tool for better living.
As an honorary member of the International Sleep Products Association (ISPA), SweetNight is committed to health and sustainability, ensuring a safe and comfortable sleep environment for every user. Its fabrics are OEKO-TEX certified and its foam is CertiPUR-US certified.
"Sleep is no longer a luxury-it's a necessity," says a SweetNight spokesperson. "CoolNest™ was born from our commitment to helping people sleep deeper, cooler, and better.
About SweetNight
SweetNight is a rapidly growing global mattress and sleep solutions company bringing high quality sleep related products to the world.
Starting from humble beginnings as an affordable mattress manufacturer, SweetNight realised that "modern sleepers needed modern sleep solutions", and began developing high-quality mattresses using eco-friendly production techniques. The initial SweetNight product line, which focused on affordable luxury was a great success in the American market, with endorsement from industry experts and media such as Forbes, SleepFoundation, Slumber Yard and more.
The CoolNest™ Memory Foam Mattress is now available for purchase on SweetNight.com as well as on their Amazon, Wayfair and Walmart stores.
Cooler Nights, Better Mornings Start Now.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
40 minutes ago
- Globe and Mail
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Should you chase high yields from slow-growing businesses or invest in lower-yield providers with more predictable cash flows? Lately, Pfizer (NYSE: PFE) and Prologis (NYSE: PLD) have been perfect examples of the trade-off between attractive yields and dividend growth. Pfizer offers a sky-high yield that's climbing slowly. Prologis offers a much lower yield, but it's been raising its payout at a remarkable pace. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Here's a closer look at both to help you decide which one fits your goals. Pfizer Shares of Pfizer have fallen about 62% from their COVID-19 pandemic highs. The stock is way down, but the company has raised its payout every year since 2009. At its beaten-down price, this stock offers an eye-popping 7.3% dividend yield. Pfizer's COVID-19 vaccine, Comirnaty, and antiviral treatment, Paxlovid, drove adjusted earnings up to $6.58 per share in 2022. Sinking demand for COVID-19 vaccines and treatments reduced adjusted earnings to just $3.11 per share last year. In 2025, Pfizer expects a significant earnings contraction. At the midpoint of the guided range management provided this April, adjusted earnings are expected to fall by 6.8% this year. The $2.80 per share management expects at the low end of the guided range is more than enough to support a dividend payout currently set at an annualized $1.72 annually, but there could be further contractions ahead. Eliquis is a next-generation blood thinner that Pfizer markets in collaboration with Bristol Myers Squibb. It's currently responsible for 14% of Pfizer's total revenue and is likely to lose ground to generic competition in the lucrative U.S. market in 2028. Long before Eliquis loses ground to generic competition, the company's lead growth driver, Vyndaquel, could stumble. BridgeBio launched a competing treatment called Attruby in late 2024, and it's been exceeding expectations. Pfizer's facing patent cliffs, but it also has one of the most productive development pipelines in the industry. Last year alone, the Food and Drug Administration issued more than a dozen approvals to new Pfizer treatments and several that are already on the market. With plenty of new products to market, the drugmaker has a good chance to continue its payout-raising streak in the decade ahead. Prologis As more folks do their shopping online, demand for warehouses that can support e-commerce has soared. By anticipating the demand, Prologis has become the world's largest real estate investment trust (REIT) that everyday investors can buy shares of. Fear and uncertainty regarding the taxes businesses need to pay when importing goods to the U.S. have pressured the stock. It's down about 12% from a peak it set in March. At its beaten-down price, it offers a 3.7% yield. Prologis has been able to raise its dividend by 11.7% annually over the past five years. At this pace, investors who buy at recent prices could begin receiving a double-digit yield on cost in less than a decade. Amazon, Home Depot, and FedEx are Prologis' largest customers. These three tenants are responsible for only 8.2% of the rent payments Proligis receives every month. This high level of diversification is a big reason it can boast industry-leading credit ratings. With an A2 rating from Moody's and an A rating from S&P Global, the weighted average interest rate on Prologis' outstanding debts was just 3.1% at the end of March. Acquiring and developing properties is an important part of this REIT's business, but it also acts as a lender. With an enviable credit rating, it can produce a strong profit while offering rates that its smaller competitors can't match. For companies that own their warehouses, selling them to Prologis and leasing them back is often their lowest-cost source of capital. With the vast majority of the world's logistics real estate still owned by the companies that use it, Prologis could continue growing at a rapid pace for decades to come. Pfizer offers a yield that's almost twice as high as Prologis's, but the pharmaceutical giant has been raising its payout at less than half the pace of the logistics REIT. Pfizer might be a good option for folks near retirement age. For income-seeking investors, though, Prologis seems like the better dividend stock to buy now. Should you invest $1,000 in Prologis right now? Before you buy stock in Prologis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Prologis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Cory Renauer has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Bristol Myers Squibb, FedEx, Home Depot, Moody's, Pfizer, Prologis, and S&P Global. The Motley Fool recommends BridgeBio Pharma and recommends the following options: long January 2026 $90 calls on Prologis. The Motley Fool has a disclosure policy.
National Post
4 hours ago
- National Post
Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research
Article content TOKYO & SUNNYVALE, Calif. — Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of infectious disease testing. This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio's Silicon Valley wholly-owned subsidiary, Fluxus, Inc. Greater test sensitivity can better inform treatment decisions in the clinic, as well as accelerate studies towards therapeutics and preventive strategies against infectious disease threats worldwide. Article content 'Infectious diseases remain one of the greatest global health challenges of our time,' says Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. 'By working with the Stanford Clinical Virology Laboratory under the direction of Professor Benjamin Pinsky and the Stanford Clinical Microbiology Laboratory under the direction of Professor Niaz Banaei, we are bringing together world-class scientific expertise, cutting-edge technology, and global health insights. This collaboration underscores our shared vision to create a healthier, more resilient world.' Article content Article content 'This collaboration represents a significant step forward in our mission to improve public health globally, by combining Fujirebio's global IVD expertise and Fluxus' ultrasensitive detection systems with Stanford's world-renowned research,' says Dr. Peter Wagner, President and CEO of Fluxus, Inc. 'We are thrilled to be working with Stanford University's prestigious infectious disease experts.' Article content About Fujirebio Article content Fujirebio, a member of H.U. Group Holdings Inc., is an R&D-driven company constantly developing new IVD testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe, and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of platforms. For more information, please visit Article content About Fluxus Article content Article content Article content Article content Article content Contacts Article content
CBC
4 hours ago
- CBC
Vets find surprise while trying to save endangered turtle hit by boat
Turns out Pennywise the sea turtle was carrying eggs A group of conservationists has reason to celebrate after rescuing an endangered sea turtle and finding out they may have saved even more turtles in the process. On May 19, conservationists from Inwater Research Group found a floating loggerhead sea turtle off Florida's Atlantic coast with significant blunt force trauma to her shell. The conservationists took the turtle to veterinarians at Loggerhead Marinelife Center in Juno Beach, Florida, where they began treating the reptile. Loggerhead Marine Centre is a non-profit conservation organization. The vets suspected the turtle — which they named Pennywise — was hit by a boat. Unfortunately, they hit a snag. To assess the extent of Pennywise's injuries, they wanted to put her into a computed tomography (CT) scanner, which uses X-rays to help health-care workers take photos of the inside of her body. WATCH — Female sea turtles are outnumbering males in Florida But at 137 kilograms (302 pounds), Pennywise was too big for their machine. The veterinary team took her to a nearby hospital to see if she could fit inside a CT machine meant for humans, but she was too big for that as well. Next, they took her to a horse hospital to use its CT machine and — thankfully — Pennywise fit. The imaging showed some damage to bones that surround the spinal cord. The vets put the turtle on special antibiotics to help her heal. 'Luckily, right now, her neurologic exam shows that all those nerves are intact. And that is a great sign for her,' Heather Barron, the chief science officer and veterinarian at Loggerhead, told The Associated Press. But the results from the CT scan weren't all bad. Turns out Pennywise is carrying eggs. 'We hope we'll be able to get her back out there into the wild as soon as possible so that she can lay those eggs,' Barron said. The centre will continue to monitor Pennywise to make sure her injuries don't get worse, Barron said, and as soon as her wounds are healed enough, they'll put her back into the wild.
